ClinicalTrials.govpublic full text
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
non-small cell lung cancer, nsclc, non-squamous nsclc, th-4000, low-oxygen conditions, hypoxia, squamous cell carcinoma, tarloxotinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 886523
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.